AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11838623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 11838623 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 82
Study 9272406 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg)
Number of subjects: 12
Study 9272406 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg)
Number of subjects: 12
Study 9272406 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (Valsartan + Furosemide)
Number of subjects: 12
Study 7514046 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 600 U/kg three times per week
Number of subjects: 35
Study 7514046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 7514046 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) and G-CSF
Number of subjects: 35
Study 7514046 — intervention group
Group type: COMPARATOR
Intervention: Placebo and G-CSF
Number of subjects: 35
Study 3069882 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 35
Study 3069882 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 35
Study 3069882 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline and Nortriptyline
Number of subjects: 35
Study 29252039 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) 35g
Number of subjects: 31
Study 29252039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) 35g
Number of subjects: 31
Study 27105016 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy for Adolescents (PE-A)
Number of subjects: 61
Study 27105016 — intervention group
Group type: COMPARATOR
Intervention: Client-Centered Therapy (CCT)
Number of subjects: 61
Study 27105016 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PE-A and CCT
Number of subjects: 61
Study 25148231 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 67
Study 25148231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 23581800 — intervention group
Group type: EXPERIMENTAL
Intervention: Project U‐Turn, a comprehensive sex education program
Number of subjects: 973
Study 23581800 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 973
Study 19756902 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive coupling electrical stimulation by Osteospine (active group)
Number of subjects: 51
Study 19756902 — intervention group
Group type: COMPARATOR
Intervention: Low intensity pulse (control group)
Number of subjects: 51
Study 19109497 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial random noise stimulation (tRNS)
Number of subjects: 80
Study 16607188 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed group (welding fumes)
Number of subjects: 22
Study 16607188 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexposed)
Number of subjects: 22
Study 12732600 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) combined with norepinephrine (NE)
Number of subjects: 48
Study 12732600 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine (NE) alone
Number of subjects: 48
Study 10976551 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate (200 mg single oral dose)
Number of subjects: 42
Study 8470716 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue disposable contact lens
Number of subjects: 37
Study 8470716 — intervention group
Group type: COMPARATOR
Intervention: CSI traditional daily-wear lens
Number of subjects: 37
Study 8470716 — intervention group
Group type: COMPARATOR
Intervention: CSI lens
Number of subjects: 37
Study 8470716 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue lens
Number of subjects: 37
Study 8470716 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall lens preference
Number of subjects: 37
Study 8470716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens comfort
Number of subjects: 37
Study 8470716 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens handling
Number of subjects: 37
Study 8470716 — intervention group
Group type: EXPERIMENTAL
Intervention: Rate or cost of torn lenses
Number of subjects: 37
Study 3543073 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate 12% lotion applied twice daily for 4 weeks
Number of subjects: 0
Study 3543073 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 3543073 — intervention group
Group type: COMPARATOR
Intervention: Petrolatum cream
Number of subjects: 0
Study 29523562 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Epworth Sleepiness Scale (ESS)
Number of subjects: 112
Study 29523562 — intervention group
Group type: COMPARATOR
Intervention: Paper Epworth Sleepiness Scale (ESS)
Number of subjects: 112
Study 25893397 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular taping (NT)
Number of subjects: 40
Study 25893397 — intervention group
Group type: COMPARATOR
Intervention: Sham tape
Number of subjects: 40
Study 25842933 — intervention group
Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 26
Study 25842933 — intervention group
Group type: EXPERIMENTAL
Intervention: Prometheus
Number of subjects: 26
Study 22445938 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation with polyethylene glycol on the morning of the colonoscopy (study group)
Number of subjects: 282
Study 22445938 — intervention group
Group type: COMPARATOR
Intervention: Preparation with polyethylene glycol on the previous afternoon (control group)
Number of subjects: 282
Study 20457556 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of financial incentive (£10 Amazon gift voucher)
Number of subjects: 485
Study 20457556 — intervention group
Group type: COMPARATOR
Intervention: No knowledge of financial incentive
Number of subjects: 485
Study 18721702 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular biology technique (PCR testing)
Number of subjects: 29
Study 18721702 — intervention group
Group type: COMPARATOR
Intervention: Traditional Gram stain and organism culture
Number of subjects: 29
Study 16356801 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 10305
Study 16356801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study 12033657 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk Skills Training Program (RSTP)
Number of subjects: 300
Study 12033657 — intervention group
Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 300
Study 12033657 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Abuse and Resistance Education (DARE-A)
Number of subjects: 300
Study 10715368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol in triphasic combination with norgestimate
Number of subjects: 37
Study 10715368 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestodene
Number of subjects: 37
Study 8924393 — intervention group
Group type: EXPERIMENTAL
Intervention: Video test for assessing interviewing skills
Number of subjects: 0
Study 8924393 — intervention group
Group type: COMPARATOR
Intervention: Standardized patients
Number of subjects: 0
Study 2026464 — intervention group
Group type: EXPERIMENTAL
Intervention: Level I T, 150-300 mg (n = 24)
Number of subjects: 58
Study 2026464 — intervention group
Group type: EXPERIMENTAL
Intervention: Level II T, 450-600 mg (n = 25)
Number of subjects: 58
Study 2026464 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 9)
Number of subjects: 58
Study 7390209 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated home services (experimental condition)
Number of subjects: 71
Study 7390209 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 71
Study 30612986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof 1% twice daily
Number of subjects: 227
Study 30612986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof 1% once daily
Number of subjects: 227
Study 30612986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof 0.5% twice daily
Number of subjects: 227
Study 30612986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof 0.5% once daily
Number of subjects: 227
Study 30612986 — intervention group
Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 227
Study 30612986 — intervention group
Group type: COMPARATOR
Intervention: Vehicle once daily
Number of subjects: 227
Study 30612986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapinarof (all groups)
Number of subjects: 227
Study 30612986 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (all groups)
Number of subjects: 227
Study 28103935 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recruitment strategies
Number of subjects: 301
Study 28103935 — intervention group
Group type: COMPARATOR
Intervention: Passive recruitment strategies
Number of subjects: 301
Study 26286707 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - 20 weeks of physical exercise training, 3 sessions of 20 minutes per week, focusing on neck and shoulder muscles.
Number of subjects: 69
Study 26286707 — intervention group
Group type: COMPARATOR
Intervention: Reference Group (RG) - No training.
Number of subjects: 69
Study 26286707 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 69
Study 26286707 — intervention group
Group type: COMPARATOR
Intervention: Reference Group (RG)
Number of subjects: 69
Study 24024772 — intervention group
Group type: EXPERIMENTAL
Intervention: Oatmeal
Number of subjects: 48
Study 24024772 — intervention group
Group type: COMPARATOR
Intervention: RTEC
Number of subjects: 48
Study 20532541 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (AC)
Number of subjects: 67
Study 20532541 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (M)
Number of subjects: 67
Study 18798237 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial (TR) approach
Number of subjects: 307
Study 18798237 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral (TF) approach
Number of subjects: 307
Study 16604127 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerol-induced hyperhydration (GIH) - 1.2 g glycerol/kg bodyweight with 26 mL/kg BW of water-aspartame-flavored fluid
Number of subjects: 6
Study 16604127 — intervention group
Group type: COMPARATOR
Intervention: Water-induced hyperhydration (WIH) - water-aspartame-flavored fluid only
Number of subjects: 6
Study 14523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalin
Number of subjects: 266
Study 14523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithalamin
Number of subjects: 266
Study 14523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalin plus Epithalamin
Number of subjects: 266
Study 14523363 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymalin plus Epithalamin (annual treatment for 6 years)
Number of subjects: 266
Study 14523363 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 266
Study 10945039 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine plus sulfadoxine-pyrimethamine
Number of subjects: 0
Study 10945039 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 0
Study 8866204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 8866204 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase during 1 h (1,500,000 U)
Number of subjects: 100
Study 8866204 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase during 48 h (250,000 U for 1 h and then 100,000 U for 48 h)
Number of subjects: 100
Study 1631487 — intervention group
Group type: EXPERIMENTAL
Intervention: Power toothbrushing
Number of subjects: 14
Study 1631487 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrushing with conventional fluoride toothpaste
Number of subjects: 14
Study 1631487 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine/fluoride gel
Number of subjects: 14
Study 6091840 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous bicarbonate (150 mmol)
Number of subjects: 16
Study 6091840 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline
Number of subjects: 16
Study 28456864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac™ (10 μg, 3 doses at 0, 1, and 6 months for naïve patients; 20 μg for previously vaccinated non-responders)
Number of subjects: 86
Study 28456864 — intervention group
Group type: COMPARATOR
Intervention: Engerix B® (40 μg, 4 doses at 0, 1, 2, and 6 months)
Number of subjects: 86
Study 28456864 — intervention group
Group type: EXPERIMENTAL
Intervention: Sci-B-Vac™
Number of subjects: 86
Study 28456864 — intervention group
Group type: COMPARATOR
Intervention: Engerix B®
Number of subjects: 86
Study 27250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN; receiving conventional perioperative management via a CVC)
Number of subjects: 40
Study 27250846 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN; receiving perioperative management without a CVC)
Number of subjects: 40
Study 27250846 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 40
Study 27250846 — intervention group
Group type: COMPARATOR
Intervention: Peripheral parenteral nutrition (PPN)
Number of subjects: 40
Study 25636499 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity cognitive concerns
Number of subjects: 106
Study 25636499 — intervention group
Group type: COMPARATOR
Intervention: Negative affect
Number of subjects: 106
Study 25636499 — intervention group
Group type: COMPARATOR
Intervention: Thwarted belongingness and insomnia
Number of subjects: 106
Study 24152421 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased spacing and eventual discontinuation of TNF blockers after 6 months
Number of subjects: 180
Study 24152421 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 180
Study 21185726 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric muscle strength of the lower limbs measured using hand held dynamometry (Nm/kg)
Number of subjects: 25
Study 21185726 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D gait analysis using VICON system
Number of subjects: 25
Study 21185726 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of muscle strength
Number of subjects: 25
Study 18729243 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia (2.4 g) plus Amorphophallus konjac (1.5 g)
Number of subjects: 58
Study 18729243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 17296074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 60
Study 17296074 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of one's coping resources therapy
Number of subjects: 60
Study 17296074 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 60
Study 17296074 — intervention group
Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 60
Study 12806521 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans (various formulations including oral tablets, orally disintegrating tablets, nasal sprays, subcutaneous injections, suppositories)
Number of subjects: 0
Study 12806521 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10735929 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg once daily
Number of subjects: 30
Study 10735929 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg once daily
Number of subjects: 30
Study 10735929 — intervention group
Group type: COMPARATOR
Intervention: Theophylline alone
Number of subjects: 30
Study 8813266 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portasystemic stent shunts (TIPS)
Number of subjects: 70
Study 8813266 — intervention group
Group type: COMPARATOR
Intervention: Small-diameter prosthetic H-graft portacaval shunts (HGPCS)
Number of subjects: 70
Study 1444879 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiracetam
Number of subjects: 24
Study 1444879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 4061004 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 0.5 mg i.v.
Number of subjects: 65
Study 4061004 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 1.0 mg i.v.
Number of subjects: 65
Study 30831180 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher energy density (increased by 20%)
Number of subjects: 49
Study 30831180 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower energy density (decreased by 20%)
Number of subjects: 49
Study 30831180 — intervention group
Group type: COMPARATOR
Intervention: Baseline energy density
Number of subjects: 49
Study 30089680 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR alert activation
Number of subjects: 2987
Study 30089680 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alert)
Number of subjects: 2987
Study 26864436 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting (60 hours)
Number of subjects: 12
Study 25225037 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially real cigarettes
Number of subjects: 64
Study 25225037 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical cigarettes
Number of subjects: 64
Study 22517217 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (AZ) 16 mg
Number of subjects: 2
Study 22517217 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine (AM) 5 mg
Number of subjects: 2
Study 22517217 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2
Study 19733100 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief behavioral intervention (6-minute intervention video)
Number of subjects: 121
Study 19733100 — intervention group
Group type: COMPARATOR
Intervention: Standardized care (Control)
Number of subjects: 121
Study 18612741 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic training plus participation as educators in a community-based IPV prevention program
Number of subjects: 117
Study 18612741 — intervention group
Group type: COMPARATOR
Intervention: Didactic training only
Number of subjects: 117
Study 16374022 — intervention group
Group type: EXPERIMENTAL
Intervention: Impermeable bed covers
Number of subjects: 32
Study 16374022 — intervention group
Group type: COMPARATOR
Intervention: Cotton covers (Control)
Number of subjects: 32
Study 12631365 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Number of subjects: 263
Study 12631365 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol
Number of subjects: 263
Study 10966962 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered solution (solution B) - 5 ml 2% lignocaine and 5 ml 0.5% bupivacaine with pH 7.44
Number of subjects: 60
Study 10966962 — intervention group
Group type: COMPARATOR
Intervention: Plain solution (solution A) - 5 ml 2% lignocaine and 5 ml 0.5% bupivacaine (acidic)
Number of subjects: 60
Study 10966962 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 8839902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cyclophosphamide, methotrexate and fluorouracil (CMF)
Number of subjects: 90
Study 8839902 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 90
Study 1401309 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 0
Study 1401309 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 0
Study 6652049 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum extraction
Number of subjects: 304
Study 6652049 — intervention group
Group type: COMPARATOR
Intervention: Forceps delivery
Number of subjects: 304
Study 31182696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant application (no drain)
Number of subjects: 262
Study 31182696 — intervention group
Group type: COMPARATOR
Intervention: Drain (group A)
Number of subjects: 262
Study 30322505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care program
Number of subjects: 116
Study 30322505 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 116
Study 26994949 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Anesthesia (RA)
Number of subjects: 1151
Study 26994949 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 1151
Study 26994949 — intervention group
Group type: COMPARATOR
Intervention: Carotid Artery Stenting (CAS)
Number of subjects: 1151
Study 23756431 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (A-tDCS) for 10 minutes at 1 mA in the DLPFC, followed by rehabilitative cognitive training, daily for 15 days
Number of subjects: 23
Study 23756431 — intervention group
Group type: COMPARATOR
Intervention: Sham A-tDCS for 25 seconds with the same rehabilitation
Number of subjects: 23
Study 21705170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse education intervention (1‐h, one‐on‐one teaching session with a nurse educator)
Number of subjects: 227
Study 21705170 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge process (control group)
Number of subjects: 227
Study 21705170 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse education intervention
Number of subjects: 227
Study 19386430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (300 mg/m²/d) and leucovorin (75 mg/d) from Days 1 to 19 and from Days 29 to 47, carboplatin (70 mg/m² intravenously for 4 consecutive days), in three cycles every 21 days, with radiotherapy (70 Gy in 35 fractions)
Number of subjects: 72
Study 19386430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil, leucovorin, and carboplatin
Number of subjects: 72
Study 16690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/d)
Number of subjects: 4
Study 16690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (150 mg/d)
Number of subjects: 4
Study 16690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (300 mg/d)
Number of subjects: 4
Study 16690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (100 mg/d)
Number of subjects: 4
Study 16690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone (300 mg/d)
Number of subjects: 4
Study 16081626 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance group (BAL) - energy and carbohydrate replaced during exercise
Number of subjects: 16